临床研究

儿童B细胞急性淋巴细胞白血病并发培门冬酶相关急性胰腺炎的危险因素分析

  • 江小珍 ,
  • 陈秀贤 ,
  • 李文敏
展开
  • 南方医科大学附属广东省人民医院(广东省医学科学院)检验科 (广东 广州 510000 )

收稿日期: 2025-04-28

  网络出版日期: 2025-09-25

基金资助

国家自然科学基金项目(82202627)

Analysis of risk factors for pegaspargase⁃associated acute pancreatitis in childhood with B⁃cell acute lymphoblastic leukemia

  • Xiaozhen JIANG ,
  • Xiuxian CHEN ,
  • Wenming LI
Expand
  • Department of Laboratory,Guangdong Provincial People′s Hospital Affiliated to Southern Medical University(Guangdong Province Academy of Medical Sciences),Guangzhou 510000,Guangdong,China

Received date: 2025-04-28

  Online published: 2025-09-25

摘要

目的 分析接受培门冬酶(PEG-ASP)治疗的B细胞急性淋巴细胞白血病(B-ALL)并发胰腺炎(AP)患儿的临床特点及危险因素。 方法 回顾性分析2021年1月至2023年2月在医院接受PEG-ASP治疗的272例ALL并发AP患儿的一般资料、临床资料、血常规数据、白蛋白浓度和PEG-ASP累计用量,分析患儿性别、年龄、危险分层、累计培门冬酶剂量、血常规指标、白蛋白浓度与胰腺炎进展的相关性。 结果 在272例患儿中,AP发生率为8.5%(23/272),AP与性别、年龄、体质量指数(BMI)、危险分层分布、累计培门冬酶剂量、血红蛋白浓度、血小板计数和单核细胞计数关联无统计学意义(P > 0.05),但与白细胞计数、中性粒细胞计数、淋巴细胞计数、中性粒细胞/淋巴细胞比值、血小板/淋巴细胞比值和白蛋白浓度有显著相关性(P < 0.05)。logistic回归分析进一步显示,白细胞计数、中性粒细胞计数、淋巴细胞计数、白蛋白浓度与PEG-ASP相关AP的发生有关(P < 0.05)。ROC分析中发现,白细胞计数、淋巴细胞计数和白蛋白浓度可以提示与PEG-ASP相关AP的发生。 结论 白细胞计数、中性粒细胞计数、淋巴细胞计数、白蛋白浓度是儿童B-ALL并发培门冬酶相关AP的危险因素。尤其是在血常规检查中观察到白细胞计数、淋巴细胞计数和白蛋白浓度检查中白蛋白浓度的异常有助于早期识别B-ALL并发PEG-ASP相关AP的高危患儿。

本文引用格式

江小珍 , 陈秀贤 , 李文敏 . 儿童B细胞急性淋巴细胞白血病并发培门冬酶相关急性胰腺炎的危险因素分析[J]. 实用医学杂志, 2025 , 41(18) : 2853 -2858 . DOI: 10.3969/j.issn.1006-5725.2025.18.010

Abstract

Objective To analyze the clinical characteristics and risk factors of children with B-cell acute lymphoblastic leukemia (B-ALL) who developed acute pancreatitis (AP) after treatment with pegaspargase (PEG-ASP). Methods A retrospective analysis was conducted on the general data, clinical data, blood routine data, albumin concentration, and cumulative dose of PEG-ASP of 272 children with ALL complicated with AP who received PEG-ASP treatment in the hospital from January 2021 to February 2023. The correlations between gender, age, risk stratification, cumulative dose of pegaspargase, blood routine indicators, albumin concentration and the progression of pancreatitis were analyzed. Results Among the 272 children, the incidence of AP was 8.5% (23/272). There was no statistically significant correlation between AP and gender, age, body mass index (BMI), risk stratification, cumulative dose of pegaspargase, hemoglobin concentration, platelet count and monocyte count (P > 0.05), but there was a significant correlation with white blood cell count, neutrophil count, lymphocyte count, neutrophil/lymphocyte ratio, platelet/lymphocyte ratio and albumin concentration (P < 0.05). Logistic regression analysis further showed that white blood cell count, neutrophil count, lymphocyte count and albumin concentration were related to the occurrence of PEG-ASP-related AP (P < 0.05). ROC analysis found that white blood cell count, lymphocyte count and albumin concentration could predict the occurrence of PEG-ASP-related AP. Conclusions White blood cell count, neutrophil count, lymphocyte count and albumin concentration are risk factors for PEG-ASP-related AP in children with B-ALL. Especially, abnormal white blood cell count, lymphocyte count and albumin concentration in blood routine examination can help identify high-risk children with B-ALL complicated with PEG-ASP-related AP at an early stage.

参考文献

[1] MALARD F, MOHTY M. Acute lymphoblastic leukaemia[J]. Lancet, 2020,395(10230): 1146-1162. doi:10.1016/s0140-6736(19)33018-1
[2] LEE M, HAMILTON J A G, TALEKAR G R, et al. Obesity-induced galectin-9 is a therapeutic target in B-cell acute lymphoblastic leukemia[J]. Nat Commun, 2022,13(1): 1157. doi:10.1038/s41467-022-28839-y
[3] 强晓, 耿贝贝, 刘四喜, 等. 转录组学技术在急性白血病诊治中的应用研究进展[J]. 实用医学杂志, 2023,39(22): 3010-3014. doi:10.3969/j.issn.1006-5725.2023.22.027
[4] FANG H, WANG W, MEDEIROS L J. Burkitt lymphoma[J]. Hum Pathol, 2025,156: 105703. doi:10.1016/j.humpath.2024.105703
[5] J?DRASZEK K, MALCZEWSKA M, PARYSEK-WóJCIK K, et al. Resistance Mechanisms in Pediatric B-Cell Acute Lymphoblastic Leukemia[J]. Int J Mol Sci, 2022,23(6):3067. doi:10.3390/ijms23063067
[6] TEACHEY D T, DEVIDAS M, WOOD B L, et al. Children's Oncology Group Trial AALL1231: A Phase Ⅲ Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma[J]. J Clin Oncol, 2022,40(19): 2106-2118. doi:10.1200/jco.21.02678
[7] HAYASHI R J, WINTER S S, DUNSMORE K P, et al. Successful Outcomes of Newly Diagnosed T Lymphoblastic Lymphoma: Results From Children's Oncology Group AALL0434[J]. J Clin Oncol, 2020,38(26): 3062-3070. doi:10.1200/jco.20.00531
[8] VROOMAN L M, BLONQUIST T M, STEVENSON K E, et al. Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 11-001[J]. J Clin Oncol, 2021,39(31): 3496-3505. doi:10.1200/jco.20.03692
[9] CHEN C, LI J, CHEN Y, et al. The correlation of asparaginase enzyme activity levels after PEG-asparaginase administration with clinical characteristics and adverse effects in Chinese paediatric patients with acute lymphoblastic leukaemia[J]. Br J Haematol, 2024,205(2): 624-633. doi:10.1111/bjh.19605
[10] WANG J, SHEN S, HU B, et al. Successful use of trametinib and dasatinib combined with chemotherapy in the treatment of Ph-positive B-cell acute lymphoblastic leukemia: A case report[J]. Medicine (Baltimore), 2021,100(25): e26440. doi:10.1097/md.0000000000026440
[11] LYNGGAARD L S, RANK C U, ALS-NIELSEN B, et al. PEG-asparaginase treatment regimens for acute lymphoblastic leukaemia in children: A network meta-analysis[J]. Cochrane Database Syst Rev, 2023, 5(5): CD14570. doi:10.1002/14651858.cd014570.pub2
[12] WU J, CHEN C, HUANG S, et al. Correlation of L-asp Activity, Anti-L-asp Antibody, Asn and Gln With Adverse Events Especially Anaphylaxis Risks in PEG-asp-Contained Regime Treated Pediatric ALL Patients[J]. Technol Cancer Res Treat, 2020,19: 1079247761. doi:10.1177/1533033820980113
[13] HOSHITSUKI K, ZHOU Y, MILLER A M, et al. Rituximab administration in pediatric patients with newly diagnosed acute lymphoblastic leukemia[J]. Leukemia, 2023,37(9): 1782-1791. doi:10.1038/s41375-023-01992-z
[14] 中华医学会儿科学分会血液学组, 编辑委员会中华儿科杂志. 儿童急性淋巴细胞白血病诊疗建议(第四次修订)[J]. 中华儿科杂志, 2014, 52(9): 641-644.
[15] WALL J M. Clinical Guideline Highlights for the Hospitalist: Management of Acute Pancreatitis in the Pediatric Population[J]. J Hosp Med, 2019,14(12): 762-763. doi:10.12788/hm.3285
[16] LI X, ZHANG Y, MIXDORF J C, et al. Development and Preclinical Evaluation of [(64)Cu]Cu-NOTA-ABDB6: A CD70 and Albumin Dual-Binding Tracer with Improved Pharmacokinetics[J]. J Nucl Med, 2025,66(4): 552-558. doi:10.2967/jnumed.124.268835
[17] RAHIMAN E A, BAKHSHI S, DEEPAM P, et al. Outcome and prognostic factors in childhood B non-Hodgkin lymphoma from India: Report by the Indian Pediatric Oncology Group (InPOG-NHL-16-01 study)[J]. Pediatr Hematol Oncol, 2022,39(5): 391-405. doi:10.1080/08880018.2021.2002485
[18] THOMAS S, MAHAPATRA M, SETH T, et al. Evaluation of Nutritional Status During Induction Chemotherapy in Patients With Acute Leukemia[J]. Cureus, 2025,17(5): e83547.
[19] LIBBUS I, NEARING B D, AMURTHUR B, et al. Quantitative evaluation of heartbeat interval time series using Poincaré analysis reveals distinct patterns of heart rate dynamics during cycles of vagus nerve stimulation in patients with heart failure[J]. J Electrocardiol, 2017,50(6): 898-903. doi:10.1016/j.jelectrocard.2017.06.007
[20] DUNSMORE K P, WINTER S S, DEVIDAS M, et al. Children's Oncology Group AALL0434: A Phase Ⅲ Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia[J]. J Clin Oncol, 2020,38(28): 3282-3293. doi:10.1200/jco.20.00256
[21] MESEGUé M, ALONSO-SALADRIGUES A, PéREZ-JAUME S, et al. Lower incidence of clinical allergy with PEG-asparaginase upfront versus the sequential use of native E. coli asparaginase followed by PEG-ASP in pediatric patients with acute lymphoblastic leukemia[J]. Hematol Oncol, 2021,39(5): 687-696.
[22] CUI J, JIANG L, XU B, et al. L-asparaginase activity and anti-L-asparaginase antibody as biomarkers in estimating PEG-asp-related anaphylaxis risk in childhood acute lymphoblastic leukemia patients[J]. Allergol Immunopathol (Madr), 2023,51(3): 28-35. doi:10.15586/aei.v51i3.771
[23] MATTANO L A J, DEVIDAS M, MALONEY K W, et al. Favorable Trisomies and ETV6-RUNX1 Predict Cure in Low-Risk B-Cell Acute Lymphoblastic Leukemia: Results From Children's Oncology Group Trial AALL0331[J]. J Clin Oncol, 2021,39(14): 1540-1552. doi:10.1200/jco.20.02370
[24] LIU C, YANG W, DEVIDAS M, et al. Clinical and Genetic Risk Factors for Acute Pancreatitis in Patients With Acute Lymphoblastic Leukemia[J]. J Clin Oncol, 2016,34(18): 2133-2140. doi:10.1200/jco.2015.64.5812
[25] 许乐乐, 陈彦君, 陆件, 等. 基于肠道生物标志物评价肠内营养补充益生菌治疗重症胰腺炎的获益与限制[J]. 实用医学杂志, 2024,40(24): 3458-3467.
[26] 赖肖蓉. 培门冬酶诱发儿童急性胰腺炎的危险因素及其严重程度预测分析[D]. 广州: 南方医科大学, 2024. doi:10.3760/cma.j.cn101070-20230602-00440
文章导航

/